160 related articles for article (PubMed ID: 19522163)
21. The use of the monoclonal antibody mesothelin in the diagnosis of malignant mesothelioma in pleural biopsies.
Galloway ML; Murray D; Moffat DF
Histopathology; 2006 May; 48(6):767-9. PubMed ID: 16681698
[No Abstract] [Full Text] [Related]
22. The established and future biomarkers of malignant pleural mesothelioma.
Panou V; Vyberg M; Weinreich UM; Meristoudis C; Falkmer UG; Røe OD
Cancer Treat Rev; 2015 Jun; 41(6):486-95. PubMed ID: 25979846
[TBL] [Abstract][Full Text] [Related]
23. Serum mesothelin, osteopontin and vimentin: useful markers for clinical monitoring of malignant pleural mesothelioma.
Bonotti A; Simonini S; Pantani E; Giusti L; Donadio E; Mazzoni MR; Chella A; Marconi L; Ambrosino N; Lucchi M; Mussi A; Cristaudo A; Foddis R
Int J Biol Markers; 2017 Mar; 32(1):e126-e131. PubMed ID: 27646775
[TBL] [Abstract][Full Text] [Related]
24. Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma.
Creaney J; Dick IM; Segal A; Musk AW; Robinson BW
Lung Cancer; 2013 Dec; 82(3):491-8. PubMed ID: 24161718
[TBL] [Abstract][Full Text] [Related]
25. Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma.
Grigoriu B; Chahine B; Zerimech F; Grégoire M; Balduyck M; Copin MC; Devos P; Lassalle P; Scherpereel A
Clin Biochem; 2009 Jul; 42(10-11):1046-50. PubMed ID: 19302997
[TBL] [Abstract][Full Text] [Related]
26. Soluble markers for diagnosis of malignant pleural mesothelioma.
Cristaudo A; Bonotti A; Simonini S; Bruno R; Foddis R
Biomark Med; 2011 Apr; 5(2):261-73. PubMed ID: 21473730
[TBL] [Abstract][Full Text] [Related]
27. Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma.
Shiomi K; Hagiwara Y; Sonoue K; Segawa T; Miyashita K; Maeda M; Izumi H; Masuda K; Hirabayashi M; Moroboshi T; Yoshiyama T; Ishida A; Natori Y; Inoue A; Kobayashi M; Sakao Y; Miyamoto H; Takahashi K; Hino O
Clin Cancer Res; 2008 Mar; 14(5):1431-7. PubMed ID: 18316566
[TBL] [Abstract][Full Text] [Related]
28. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J
Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology.
Canessa PA; Franceschini MC; Ferro P; Battolla E; Dessanti P; Manta C; Sivori M; Pezzi R; Fontana V; Fedeli F; Pistillo MP; Roncella S
Cancer Invest; 2013 Jan; 31(1):43-50. PubMed ID: 23249166
[TBL] [Abstract][Full Text] [Related]
30. Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers.
Maeda M; Hino O
Pathol Int; 2006 Nov; 56(11):649-54. PubMed ID: 17040286
[TBL] [Abstract][Full Text] [Related]
31. [Expression of mesothelin as a potential diagnostic marker in mesothelioma].
Kuribayashi K; Fukuoka K; Nakajima T; Miyake M; Miyata S; Tamura K; Iida S; Yamada S; Murakami A; Hirano H; Nakano T
Nihon Kokyuki Gakkai Zasshi; 2008 Jan; 46(1):3-9. PubMed ID: 18260303
[TBL] [Abstract][Full Text] [Related]
32. Malignant pleural mesothelioma: an update on biomarkers and treatment.
Ray M; Kindler HL
Chest; 2009 Sep; 136(3):888-896. PubMed ID: 19736192
[TBL] [Abstract][Full Text] [Related]
33. Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma.
Yamada S; Tabata C; Tabata R; Fukuoka K; Nakano T
Clin Chem Lab Med; 2011 Oct; 49(10):1721-6. PubMed ID: 21692685
[TBL] [Abstract][Full Text] [Related]
34. The usefulness of CYFRA 21-1 in diagnosing and monitoring malignant pleural mesothelioma.
Marukawa M; Hiyama J; Shiota Y; Ono T; Sasaki N; Taniyama K; Mashiba H
Acta Med Okayama; 1998 Apr; 52(2):119-23. PubMed ID: 9588228
[TBL] [Abstract][Full Text] [Related]
35. Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma.
Mundt F; Nilsonne G; Arslan S; Csürös K; Hillerdal G; Yildirim H; Metintas M; Dobra K; Hjerpe A
PLoS One; 2013; 8(8):e72030. PubMed ID: 23991032
[TBL] [Abstract][Full Text] [Related]
36. Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels.
Rai AJ; Flores RM; Mathew A; Gonzalez-Espinoza R; Bott M; Ladanyi M; Rusch V; Fleisher M
Clin Chem Lab Med; 2010 Feb; 48(2):271-8. PubMed ID: 20131968
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis.
Luo L; Shi HZ; Liang QL; Jiang J; Qin SM; Deng JM
Respir Med; 2010 Jan; 104(1):149-56. PubMed ID: 19945835
[TBL] [Abstract][Full Text] [Related]
38. Value of mesothelin immunostaining in the diagnosis of mesothelioma.
Ordóñez NG
Mod Pathol; 2003 Mar; 16(3):192-7. PubMed ID: 12640097
[TBL] [Abstract][Full Text] [Related]
39. Asbestos-related disease: screening and diagnosis.
Rodríguez Portal JA
Adv Clin Chem; 2012; 57():163-85. PubMed ID: 22870590
[TBL] [Abstract][Full Text] [Related]
40. Mesothelin-family proteins and diagnosis of mesothelioma.
Robinson BW; Creaney J; Lake R; Nowak A; Musk AW; de Klerk N; Winzell P; Hellstrom KE; Hellstrom I
Lancet; 2003 Nov; 362(9396):1612-6. PubMed ID: 14630441
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
